Study APV20002: Safety and Efficacy Results Through Week 684 for Pediatric Participants Living with HIV-1 Treated with Ritonavir-Boosted Fosamprenavir Oral Solution–Based Antiretroviral Therapy
AIDS Research and Human Retroviruses · 2024
DOI: 10.1089/aid.2024.0020 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift AIDS Research and Human Retroviruses, 2024. Verfasst von Lisa L Ross und 9 weiteren Autor:innen. Beteiligte Einrichtung: ViiV Healthcare, Durham, North Carolina, USA. Hauptthemen laut MEDLINE: HIV Infections, Ritonavir, Carbamates, Sulfonamides. Die Arbeit nennt 10 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
APV20002 was a multicenter, international, open-label study that began in 2003 investigating the pharmacokinetics, efficacy, and safety of ritonavir-boosted fosamprenavir (FPV/r) oral solution (OS) in combination with nucleoside reverse transcriptase inhibitor-based antiretroviral therapy (ART) in participants living with HIV-1 aged 4 weeks to 39 kg or if FPV OS had no clinical benefit. Fifty-nine participants were enrolled; 5/59 received a single FPV OS visit for pharmacokinetic determinations. Most (38/54; 70%) were antiretroviral experienced; 39/59 participants had >48 weeks on treatment, 4/39 of whom discontinued after 48 weeks due to an adverse event (AE). At 48W, 88% of participants had HIV-1 RNA
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- ViiV Healthcare, Durham, North Carolina, USA.
- Department of Pediatrics and Child Health, Children's Infectious Diseases Clinical Research Unit, Stellenbosch University, Tygerberg, South Africa.
- Perinatal HIV Research Unit, University of the Witwatersrand, Johannesburg, South Africa.
- GlaxoSmithKline, Brentford, United Kingdom.
- ViiV Healthcare, Brentford, United Kingdom.
Zitieren
APA
Ross, L. L., Cotton, M. F., Cassim, H., Garges, H. P., van Dijkman, S. C., Morarji, K., Karthika, S., Danehower, S., Radford, J., & Butcher, D. (2024). Study APV20002: Safety and Efficacy Results Through Week 684 for Pediatric Participants Living with HIV-1 Treated with Ritonavir-Boosted Fosamprenavir Oral Solution–Based Antiretroviral Therapy. AIDS Research and Human Retroviruses. https://doi.org/10.1089/aid.2024.0020
Vancouver
Ross LL, Cotton MF, Cassim H, Garges HP, van Dijkman SC, Morarji K, et al. Study APV20002: Safety and Efficacy Results Through Week 684 for Pediatric Participants Living with HIV-1 Treated with Ritonavir-Boosted Fosamprenavir Oral Solution–Based Antiretroviral Therapy. AIDS Research and Human Retroviruses. 2024. doi:10.1089/aid.2024.0020
BibTeX
@article{Ross2024,
author = {Ross, Lisa L and Cotton, Mark F and Cassim, Haseena and Garges, Harmony P and van Dijkman, Sven C and Morarji, Kishen and Karthika, Supriya and Danehower, Susan and Radford, Jacob and Butcher, David},
title = {Study APV20002: Safety and Efficacy Results Through Week 684 for Pediatric Participants Living with HIV-1 Treated with Ritonavir-Boosted Fosamprenavir Oral Solution–Based Antiretroviral Therapy},
journal = {AIDS Research and Human Retroviruses},
year = {2024},
doi = {10.1089/aid.2024.0020}
}
EUVIMED